Microcap Ledger Coherus Oncology, Inc. $CHRS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Redwood City, CA
- Fiscal year end
- December 31
- Shares outstanding
- 154,500,966 [10-Q 2026-08-05]
What the company doesAI summary of filing
Coherus Oncology, Inc. is a commercial-stage oncology company that develops and commercializes immuno-oncology medicines. The company's approved product is LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor approved by the FDA in October 2023 for treating nasopharyngeal carcinoma, which the company launched in the United States in January 2024 and generates revenue through sales via specialty pharmaceutical distributors. The company also has two clinical-stage product candidates—casdozokitug and tagmokitug—targeting various cancers including hepatocellular carcinoma, head and neck cancer, and colorectal cancer. Coherus makes money through product sales of LOQTORZI and receives milestone payments and royalties from collaboration and licensing agreements with partners including Junshi Biosciences and Apotex. [10-K 2026-03-09]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $26.62M | −$58.96M | −$119.98M | $82.92M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $42.17M | $168.02M | −$138.51M | $88.88M | [10-K 2026-03-09] |
| FY ended Dec 2024 | $26.39M | $28.51M | −$20.44M | $125.99M | [10-K 2026-03-09] |
- Quarterly cash burn
- −$59.99M
- Cash runway Estimate
- ~4.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 115,213,407 | [10-Q 2024-11-06] |
| 2025-02-28 | 115,896,849 | [10-K 2025-03-17] |
| 2025-04-30 | 115,933,276 | [10-Q 2025-05-12] |
| 2025-07-31 | 116,227,275 | [10-Q 2025-08-07] |
| 2025-10-31 | 120,871,013 | [10-Q 2025-11-06] |
| 2026-02-28 | 149,889,902 | [10-K 2026-03-09] |
| 2026-04-30 | 154,249,900 | [10-Q 2026-05-11] |
| 2026-07-31 | 154,500,966 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2025-11-13; declared effective 2025-12-08 [S-3 2025-11-13]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-07-03. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-07-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-07-03] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-05 | Satvat Ali J. | grant | 30,000 | — | [4 2026-06-09] |
| 2026-06-05 | Karachun Rita A | grant | 30,000 | — | [4 2026-06-09] |
| 2026-06-05 | Newcomer Lee Nisley | grant | 30,000 | — | [4 2026-06-09] |
| 2026-06-05 | Ryan Michael Lee | grant | 30,000 | — | [4 2026-06-09] |
| 2026-06-05 | O'Donnell-Tormey Jill | grant | 30,000 | — | [4 2026-06-09] |
| 2026-06-05 | Wahlstrom Mats | grant | 30,000 | — | [4 2026-06-09] |
| 2026-06-05 | Newton Charles W. | grant | 30,000 | — | [4 2026-06-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-28 | 8-K | Other events |
| 2026-08-28 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-28 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-17 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-17 | 8-K | Material agreement entered; Material agreement terminated; New financial obligation |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-15 | 8-K | Auditor change |
| 2026-06-01 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-11 | 10-Q | Quarterly report |
Alerts for $CHRS
Email me when Coherus Oncology, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.